Apellis Pharmaceuticals (APLS) is the lead sponsor of 7 active clinical trials listed on ClinicalTrials.gov[3], including 3 Phase 3[1], 3 Phase 2[2].
Trial NCT07020832[4] evaluates Pegcetacoplan in Delayed Graft Function with a target enrollment of 320 participants. Trial NCT05809531[5] evaluates Pegcetacoplan in C3G with a target enrollment of 100 participants. Trial NCT03531255[6] evaluates Pegcetacoplan in PNH with a target enrollment of 160 participants.
APLS has 2 Form 4 insider filings recorded at the SEC in the past 30 days[7].